{"id":391949,"date":"2020-12-02T11:10:08","date_gmt":"2020-12-02T16:10:08","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=391949"},"modified":"2020-12-02T11:10:08","modified_gmt":"2020-12-02T16:10:08","slug":"invitation-to-telephone-conference-in-response-to-dagens-industris-article-published-on-december-1","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/invitation-to-telephone-conference-in-response-to-dagens-industris-article-published-on-december-1\/","title":{"rendered":"Invitation to telephone conference in response to Dagens Industri’s article published on December 1"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n LUND, Sweden<\/span>, Dec. 2, 2020<\/span> \/PRNewswire\/ — Immunovia invites investors, analysts and the media to a telephone conference with CEO Patrik Dahlen<\/span> tomorrow, Thursday, December 3<\/span>, at CET 10:00 to address an article published on di.se on December 1<\/span>: <\/b>Experts skeptical to Immunovia’s bloodtest: “Would not count on it”<\/b><\/i>\u00a0(<\/b>Experter skeptiska till Immunovias blodtest: “Skulle inte satsa p\u00e5 detta”)<\/b><\/i>.<\/b><\/p>\n

The purpose of the telephone conference is to clarify how the company’s blood test for early detection of pancreatic cancer shall be used and the timeline for start of sales at the end of Q1 2021.<\/p>\n

Immunovia’s blood test, IMMray\u2122 PanCan-d, is intended for patient groups who have an elevated risk for pancreatic cancer. There are two ways to use the test. First, it can be used to rule out pancreatic cancer in patient groups showing early or vague symptoms of the disease. The test has a high NPV (negative predictive value) at 99,3%, a necessary value for a rule out test.<\/p>\n

The second way that this test can be used is\u00a0to detect the disease,\u00a0a so called “rule-in”,\u00a0in people belonging to different risk groups, such as those with a family history of the disease or those over 50 years old with a recent diagnosis of type 2 diabetes.\u00a0<\/p>\n

\n Telephone conference<\/b>\n <\/p>\n

Immunovia’s CEO, Patrik Dahlen<\/span>, will hold a webcasted telephone conference for investors, analysts and media tomorrow, Thursday, December 3<\/span>, at CET 10.00. The telephone conference will be held in English. <\/p>\n

\n Webcast:<\/b>\u00a0https:\/\/tv.streamfabriken.com\/3-dec-press-conference<\/a><\/p>\n

\n Telephone numbers:<\/b>
\n
Sweden:\u00a0+46850558368<\/a>\u00a0
United Kingdom:\u00a0+443333009269<\/a><\/p>\n

Following the telephone conference, a recording will be available on Immunovia’s website<\/a>.<\/p>\n

\n For more information, please contact:<\/b>\n <\/p>\n

\n Patrik Dahlen<\/span>, CEO Immunovia
Email: patrik.dahlen@immunovia.com<\/a>
Tel: +46 73 376 76 64<\/p>\n

\n This is information that Immunovia is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 16<\/i>
\n .50\u00a0CET on December 2, 2020<\/span>.<\/i>\n <\/p>\n

\n About Immunovia<\/b>\n <\/p>\n

Immunovia AB is a diagnostic company that is developing and commercializing highly accurate blood tests for the early detection of cancer and autoimmune diseases based on\u00a0Immunovia’s proprietary test platform called IMMray\u2122.\u00a0Tests are based on antibody biomarker microarray analysis using advanced machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a unique “disease biomarker signature”.<\/p>\n

The company was founded in 2007, based on cancer studies and ground-breaking research in the Department of Immuntechnology at Lund<\/span> University and CREATE Health Cancer Center, Sweden<\/span>.<\/p>\n

The first product, IMMray\u2122 PanCan-d, is undergoing clinical evaluation in some of the\u00a0world’s largest clinical studies for pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1<\/a>\u00a0and is currently in the final validation phase. The company aims for a sales start at the end of Q1 2021 with subsequent commercial testing in Q2.<\/p>\n

When validated, IMMray\u2122 PanCan-d will be the first blood-based test for early diagnosis of pancreatic cancer on the market, with a potential to significantly improve patient survival and outcome.<\/p>\n

\n Immunovia Dx Laboratories located in Marlborough, Massachusetts<\/span>, USA and Lund, Sweden<\/span> will provide laboratory testing services in two accredited reference laboratories.<\/i>\n <\/p>\n

Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit\u00a0www.immunovia.com<\/a>.<\/p>\n

This information was brought to you by Cision http:\/\/news.cision.com<\/a><\/p>\n

\n https:\/\/news.cision.com\/immunovia-ab\/r\/invitation-to-telephone-conference-in-response-to-dagens-industri-s-article-published-on-december-1,c3248103<\/a>\n <\/p>\n

The following files are available for download:<\/p>\n

\n\n\n
\n

\n
\n https:\/\/mb.cision.com\/Main\/13121\/3248103\/1343376.pdf<\/a>
\n <\/span>\n <\/p>\n<\/td>\n

\n

\n Press release (PDF)<\/span>\n <\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n

\n \"Cision\" View original content:http:\/\/www.prnewswire.com\/news-releases\/invitation-to-telephone-conference-in-response-to-dagens-industris-article-published-on-december-1-301183892.html<\/a><\/p>\n

SOURCE Immunovia AB<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire LUND, Sweden, Dec. 2, 2020 \/PRNewswire\/ — Immunovia invites investors, analysts and the media to a telephone conference with CEO Patrik Dahlen tomorrow, Thursday, December 3, at CET 10:00 to address an article published on di.se on December 1: Experts skeptical to Immunovia’s bloodtest: “Would not count on it”\u00a0(Experter skeptiska till Immunovias blodtest: “Skulle inte satsa p\u00e5 detta”). The purpose of the telephone conference is to clarify how the company’s blood test for early detection of pancreatic cancer shall be used and the timeline for start of sales at the end of Q1 2021. Immunovia’s blood test, IMMray\u2122 PanCan-d, is intended for patient groups who have an elevated risk for pancreatic cancer. There are two ways to use … <\/p>\n

Continue reading “Invitation to telephone conference in response to Dagens Industri’s article published on December 1”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-391949","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nInvitation to telephone conference in response to Dagens Industri's article published on December 1 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/invitation-to-telephone-conference-in-response-to-dagens-industris-article-published-on-december-1\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Invitation to telephone conference in response to Dagens Industri's article published on December 1 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire LUND, Sweden, Dec. 2, 2020 \/PRNewswire\/ — Immunovia invites investors, analysts and the media to a telephone conference with CEO Patrik Dahlen tomorrow, Thursday, December 3, at CET 10:00 to address an article published on di.se on December 1: Experts skeptical to Immunovia’s bloodtest: “Would not count on it”\u00a0(Experter skeptiska till Immunovias blodtest: “Skulle inte satsa p\u00e5 detta”). The purpose of the telephone conference is to clarify how the company’s blood test for early detection of pancreatic cancer shall be used and the timeline for start of sales at the end of Q1 2021. Immunovia’s blood test, IMMray\u2122 PanCan-d, is intended for patient groups who have an elevated risk for pancreatic cancer. There are two ways to use … Continue reading "Invitation to telephone conference in response to Dagens Industri’s article published on December 1"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/invitation-to-telephone-conference-in-response-to-dagens-industris-article-published-on-december-1\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-02T16:10:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO09833&sd=2020-12-02\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/invitation-to-telephone-conference-in-response-to-dagens-industris-article-published-on-december-1\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/invitation-to-telephone-conference-in-response-to-dagens-industris-article-published-on-december-1\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Invitation to telephone conference in response to Dagens Industri’s article published on December 1\",\"datePublished\":\"2020-12-02T16:10:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/invitation-to-telephone-conference-in-response-to-dagens-industris-article-published-on-december-1\\\/\"},\"wordCount\":579,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/invitation-to-telephone-conference-in-response-to-dagens-industris-article-published-on-december-1\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO09833&sd=2020-12-02\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/invitation-to-telephone-conference-in-response-to-dagens-industris-article-published-on-december-1\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/invitation-to-telephone-conference-in-response-to-dagens-industris-article-published-on-december-1\\\/\",\"name\":\"Invitation to telephone conference in response to Dagens Industri's article published on December 1 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/invitation-to-telephone-conference-in-response-to-dagens-industris-article-published-on-december-1\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/invitation-to-telephone-conference-in-response-to-dagens-industris-article-published-on-december-1\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO09833&sd=2020-12-02\",\"datePublished\":\"2020-12-02T16:10:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/invitation-to-telephone-conference-in-response-to-dagens-industris-article-published-on-december-1\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/invitation-to-telephone-conference-in-response-to-dagens-industris-article-published-on-december-1\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/invitation-to-telephone-conference-in-response-to-dagens-industris-article-published-on-december-1\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO09833&sd=2020-12-02\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO09833&sd=2020-12-02\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/invitation-to-telephone-conference-in-response-to-dagens-industris-article-published-on-december-1\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Invitation to telephone conference in response to Dagens Industri’s article published on December 1\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Invitation to telephone conference in response to Dagens Industri's article published on December 1 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/invitation-to-telephone-conference-in-response-to-dagens-industris-article-published-on-december-1\/","og_locale":"en_US","og_type":"article","og_title":"Invitation to telephone conference in response to Dagens Industri's article published on December 1 - Market Newsdesk","og_description":"PR Newswire LUND, Sweden, Dec. 2, 2020 \/PRNewswire\/ — Immunovia invites investors, analysts and the media to a telephone conference with CEO Patrik Dahlen tomorrow, Thursday, December 3, at CET 10:00 to address an article published on di.se on December 1: Experts skeptical to Immunovia’s bloodtest: “Would not count on it”\u00a0(Experter skeptiska till Immunovias blodtest: “Skulle inte satsa p\u00e5 detta”). The purpose of the telephone conference is to clarify how the company’s blood test for early detection of pancreatic cancer shall be used and the timeline for start of sales at the end of Q1 2021. Immunovia’s blood test, IMMray\u2122 PanCan-d, is intended for patient groups who have an elevated risk for pancreatic cancer. There are two ways to use … Continue reading \"Invitation to telephone conference in response to Dagens Industri’s article published on December 1\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/invitation-to-telephone-conference-in-response-to-dagens-industris-article-published-on-december-1\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-02T16:10:08+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO09833&sd=2020-12-02","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/invitation-to-telephone-conference-in-response-to-dagens-industris-article-published-on-december-1\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/invitation-to-telephone-conference-in-response-to-dagens-industris-article-published-on-december-1\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Invitation to telephone conference in response to Dagens Industri’s article published on December 1","datePublished":"2020-12-02T16:10:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/invitation-to-telephone-conference-in-response-to-dagens-industris-article-published-on-december-1\/"},"wordCount":579,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/invitation-to-telephone-conference-in-response-to-dagens-industris-article-published-on-december-1\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO09833&sd=2020-12-02","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/invitation-to-telephone-conference-in-response-to-dagens-industris-article-published-on-december-1\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/invitation-to-telephone-conference-in-response-to-dagens-industris-article-published-on-december-1\/","name":"Invitation to telephone conference in response to Dagens Industri's article published on December 1 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/invitation-to-telephone-conference-in-response-to-dagens-industris-article-published-on-december-1\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/invitation-to-telephone-conference-in-response-to-dagens-industris-article-published-on-december-1\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO09833&sd=2020-12-02","datePublished":"2020-12-02T16:10:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/invitation-to-telephone-conference-in-response-to-dagens-industris-article-published-on-december-1\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/invitation-to-telephone-conference-in-response-to-dagens-industris-article-published-on-december-1\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/invitation-to-telephone-conference-in-response-to-dagens-industris-article-published-on-december-1\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO09833&sd=2020-12-02","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO09833&sd=2020-12-02"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/invitation-to-telephone-conference-in-response-to-dagens-industris-article-published-on-december-1\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Invitation to telephone conference in response to Dagens Industri’s article published on December 1"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/391949","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=391949"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/391949\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=391949"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=391949"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=391949"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}